SCHEMBL13663577

SCHEMBL13663577

Cc1cc(Nc2cncc(Nc3ccc4nc[nH]c4c3)n2)n[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 2/20 0.47
▸ JAK3 P52333 2/20 0.47
▸ ADRA2A P08913 1/20 0.46
▸ ADRA2C P18825 1/20 0.46
▸ ADRA1D P25100 1/20 0.46
▸ ADRA1A P35348 1/20 0.46
▸ ADRA1B P35368 1/20 0.46
▸ CDK1 P06493 10/20 0.46
▸ IGF1R P08069 1/20 0.43
▸ DHODH Q02127 1/20 0.43
▸ QPCT Q16769 1/20 0.43
▸ ULK1 O75385 1/20 0.42
▸ PDK1 Q15118 1/20 0.42
▸ ULK2 Q8IYT8 1/20 0.42
▸ TERT O14746 1/20 0.41
▸ P2RY14 Q15391 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13663576 0.81 EIF2AK2 (0.55) JAK2JAK3IGF1RDHODHMEN1
SCHEMBL13663490 0.80 ABCB1 (0.48) JAK2JAK3IGF1RDHODHMEN1
SCHEMBL13663537 0.80 JAK2 (0.50) JAK2JAK3IGF1RDHODHMEN1
SCHEMBL13663574 0.79 DHODH (0.55) JAK2JAK3IGF1RDHODHMEN1
SCHEMBL13663495 0.79 JAK2 (0.62) JAK2JAK3IGF1RDHODHMEN1
SCHEMBL13663554 0.79 JAK2 (0.55) JAK2JAK3IGF1RDHODHMEN1
SCHEMBL13663558 0.78 AURKA (0.54) JAK2JAK3DHODHMEN1HTT
SCHEMBL13663482 0.77 AURKA (0.53) JAK2JAK3IGF1RDHODHMEN1
SCHEMBL13663557 0.77 JAK2 (0.62) JAK2JAK3DHODH
SCHEMBL13663570 0.77 JAK2 (0.46) JAK2JAK3IGF1RDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 JAK2 39/4885JAK3 35/4885ADRA2A 2742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback